Skip to main content

Multi-tumor antigen specific cytotoxic T lymphocytes (TSA-T) directed

Immunotherapy for Malignant Pediatric Brain Tumors Employing Adoptive Cellular Therapy (IMPACT)

  • RegistryNCT06193759
  • PhasePhase 1
  • StatusRecruiting
  • ConditionMedulloblastoma, Childhood
  • SponsorChildren's National Research Institute
How IMPACT worksNCT061937591 min

What the film says

Read the transcript

The youngest children with brain tumors face a hard trade: radiation damages a growing brain, so doctors use intensive chemotherapy instead, and many relapse anyway.

The idea: after standard treatment, send in T cells trained on that child's own tumor.

At Children's National, a piece of the tumor removed at surgery is sequenced and its proteins read to find markers unique to that cancer. The child's T cells are then grown in the lab against several of those markers at once, without gene editing, and infused once therapy is complete.

An early safety study, for children under five with embryonal tumors, and recurrent ependymoma up to age thirty.

Brian Rood leads IMPACT in Washington. Public record; not medical advice.

Sources behind this film

  • ClinicalTrials.gov record NCT06193759

    Young children cannot receive irradiation; intensive chemo + stem cell rescue; many relapse; TSA-T generated after standard-of-care / salvage therapy; Proteogenomically determined tumor-specific antigens from the patient's primary tumor tissue; Multi-antigen, non-gene-modified cytotoxic T lymphocytes ("without gene editing") (+2 more lines)

The drug

What is being tested.

Participants in this study will receive TSA-T after completion of standard-of-care treatment.

Patients will undergo surgical resection, then be treated with standard-of-care therapy as required, which may include up to 3 induction chemotherapy cycles (vincristine, cyclophosphamide, cisplatin, etoposide with or without methotrexate) and up to 3 consolidation cycles (carboplatin and thiotepa, each followed by an infusion of autologous peripheral blood stem cells).

TSA-T products will be manufactured at the cell therapy Good Manufacturing Practice (GMP) facility at Children's National Hospital (CNH). Patients enrolled in the study will receive their infusions at CNH.

The study

How the trial runs.

This is an open-label phase 1 safety and feasibility study that will employ multi-tumor antigen specific cytotoxic T lymphocytes (TSA-T) directed against proteogenomically determined personalized tumor-specific antigens (TSA) derived from a patient's primary brain tumor tissues.

Young patients with embryonal central nervous system (CNS) malignancies typically are unable to receive irradiation due to significant adverse effects and are treated with intensive chemotherapy followed by autologous stem cell rescue; however, despite intensive therapy, many of these patients relapse.

Live record on ClinicalTrials.gov →

Eligibility

Who the study is looking for.

  • RECIPIENT SCREENING INCLUSION CRITERIA
  • Diagnosis (select one group):
  • Group A: New diagnosis of CNS embryonal tumors: medulloblastoma, embryonal tumor with multilayered rosettes, pineoblastoma, atypical teratoid/rhabdoid tumor, and embryonal tumor, not otherwise specified (NOS).
  • Group B: Radiographic evidence consistent with recurrent ependymoma, with planned or recent re-resection.
  • Group A: <5 years of age at enrollment
  • Group B: >1 year and <30 years of age at enrollment

Inclusion criteria as written on the registry, trimmed. The full list, with exclusions, is on the live record.

For you, or someone you love

Whether or not this trial is the one, bring AI into your corner.

A complex diagnosis brings new questions every week, in a trial and out of one. Triangle keeps your whole medical file together, reads it with you in plain language, and helps you and your family decide what to ask next.

Start your 7-day free trial

Then $9 a month. Cancel anytime.

  • Every record in one place

    Requested from your hospitals and clinics through the national networks. Add scans, pathology and anything on paper.

  • Read in plain words

    Reports explained as they come in, with lab values you can follow before treatment, during a trial and after.

  • Ready for every appointment

    Ask about your own file, and walk in with questions for your oncologist or the trial team.

  • Your people, in the loop

    Share one profile with the family helping you, and with your doctors.

Members also get a deeper analysis of their records and any sequencing data, including clinical trials that may fit, reviewed by a licensed physician before they receive it.

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.

How these trials work: what Phase 1 actually is · common questions Not clinical evidence.